RESUMEN
The use of modern chemotherapy (CT) allowed to achieve significant progress in the treatment of many malignant tumors that were previously considered fatal. Improving the efficiency of the treatment was achieved by the intensification of chemotherapy. However, intensification of chemotherapy regimes provoked increase in the number of side effects of anticancer therapy,which often lead to a decrease in the intensity of the selected mode, the additional financial costs of treating the complications and the formation of the negative attitude of the patient to treatment. Thus, the side effects of chemotherapy are the actual problem of modern oncology. The purpose of this literature review was to investigate the frequency, symptoms and ways to prevent and treat various types of toxicity of chemotherapy.
Asunto(s)
Antineoplásicos/efectos adversos , Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Náusea/tratamiento farmacológico , Neutropenia/tratamiento farmacológico , Sustancias Protectoras/uso terapéutico , Vómitos/tratamiento farmacológico , Antineoplásicos/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/patología , Enfermedad Hepática Inducida por Sustancias y Drogas/diagnóstico , Enfermedad Hepática Inducida por Sustancias y Drogas/metabolismo , Femenino , Humanos , Náusea/inducido químicamente , Náusea/diagnóstico , Náusea/metabolismo , Neutropenia/inducido químicamente , Neutropenia/diagnóstico , Neutropenia/metabolismo , Receptores de Serotonina/metabolismo , Antagonistas de la Serotonina/uso terapéutico , Vómitos/inducido químicamente , Vómitos/diagnóstico , Vómitos/metabolismoRESUMEN
Management of non-Hodgkin's lymphomas (NHL) has been significantly changed during last 40 years from radiotherapy to modern polychemotherapy with application of monoclonal antibodies. A ten year experience of the treatment of patients with B-cell NHL with rituximab application was accumulated in National Cancer Institute. The group of patients with NHL, who were treated in oncohematology department in the period from 2001 to 2010, was chosen for study of the efficacy of the treatment with rituximab. The immediate and distant results of the treatment were evaluated in this group of patients. The usage of the polychemotherapy with rituximab was highly efficient in the treatment of primary and relapsed patients with NHL. This group shows high rate of the immediate and distant results of treatment.
Asunto(s)
Anticuerpos Monoclonales de Origen Murino/uso terapéutico , Antígenos CD20/inmunología , Antineoplásicos/uso terapéutico , Linfocitos B/inmunología , Linfoma no Hodgkin/tratamiento farmacológico , Linfoma no Hodgkin/inmunología , Prevención Secundaria , Adulto , Anciano , Anticuerpos Monoclonales de Origen Murino/administración & dosificación , Antígenos CD20/metabolismo , Antineoplásicos/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Linfocitos B/citología , Biopsia , Supervivencia sin Enfermedad , Esquema de Medicación , Femenino , Humanos , Estudios Longitudinales , Linfoma no Hodgkin/mortalidad , Linfoma no Hodgkin/patología , Masculino , Persona de Mediana Edad , Rituximab , Linfocitos T/citología , Linfocitos T/inmunología , Resultado del Tratamiento , UcraniaRESUMEN
Achievements of world practice about development and prophilaxis of tromboembolic events (VTE) in cancer patients. Particular attention is paid to prevention of VTE in patients with multiply myeloma who receive chemotherapy with Thalidomide.
Asunto(s)
Fibrinolíticos/administración & dosificación , Mieloma Múltiple/tratamiento farmacológico , Talidomida/efectos adversos , Trombosis/tratamiento farmacológico , Factores de Edad , Aspirina/administración & dosificación , Aspirina/uso terapéutico , Ensayos Clínicos como Asunto , Combinación de Medicamentos , Enoxaparina/administración & dosificación , Enoxaparina/uso terapéutico , Fibrinolíticos/uso terapéutico , Humanos , Mieloma Múltiple/complicaciones , Mieloma Múltiple/fisiopatología , Factores de Riesgo , Índice de Severidad de la Enfermedad , Talidomida/administración & dosificación , Talidomida/uso terapéutico , Trombosis/complicaciones , Trombosis/fisiopatología , Warfarina/administración & dosificación , Warfarina/uso terapéuticoRESUMEN
The treatment of patients with refractory forms of Hodgkin's lymphomas in combination with chemo-radiotherapy is priority. Nevertheless, chemotherapy has to include multicomponent schemes and radiation therapy should be an addition and consolidative method to chemotherapy.
